Pyrazole Incorporated New Thiosemicarbazones: Design, Synthesis and Investigation of DPP-4 Inhibitory Effects
Open Access
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibition has been recognized as a promising approach to develop safe and potent antidiabetic agents for the management of type 2 diabetes. In this context, new thiosemicarbazones (2a–o) were prepared efficiently by the reaction of aromatic aldehydes with 4-[4-(1H-pyrazol-1-yl)phenyl]thiosemicarbazide (1), which was obtained via the reaction of 4-(1H-pyrazol-1-yl)phenyl isothiocyanate with hydrazine hydrate. Compounds 2a–o were evaluated for their DPP-4 inhibitory effects based on a convenient fluorescence-based assay. 4-[4-(1H-pyrazol-1-yl)phenyl]-1-(4-bromobenzylidene)thiosemicarbazide (2f) was identified as the most effective DPP-4 inhibitor in this series with an IC50 value of 1.266 ± 0.264 nM when compared with sitagliptin (IC50 = 4.380 ± 0.319 nM). MTT test was carried out to assess the cytotoxic effects of compounds 2a–o on NIH/3T3 mouse embryonic fibroblast (normal) cell line. According to cytotoxicity assay, compound 2f showed cytotoxicity towards NIH/3T3 cell line with an IC50 value higher than 500 µM pointing out its favourable safety profile. Molecular docking studies indicated that compound 2f presented π-π interactions with Arg358 and Tyr666 via pyrazole scaffold and 4-bromophenyl substituent, respectively. Overall, in vitro and in silico studies put emphasis on that compound 2f attracts a great notice as a drug-like DPP-4 inhibitor for further antidiabetic research.Keywords
Funding Information
- Anadolu Üniversitesi (2005S019)
This publication has 38 references indexed in Scilit:
- Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?Metabolism, 2020
- Type 2 Diabetes Mellitus: A Review of Multi-Target DrugsMolecules, 2020
- Anti-inflammatory potentials of incretin-based therapies used in the management of diabetesLife Sciences, 2020
- Current anti-diabetic agents and their molecular targets: A reviewEuropean Journal of Medicinal Chemistry, 2018
- Q&A: insulin secretion and type 2 diabetes: why do β-cells fail?BMC Biology, 2015
- Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitorsEuropean Journal of Medicinal Chemistry, 2014
- Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)Best Practice & Research Clinical Endocrinology & Metabolism, 2009
- Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes MellitusThe American Journal of Medicine, 2009
- Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetesBioorganic & Medicinal Chemistry, 2009
- DPP4 inhibitors for diabetes—What next?Biochemical Pharmacology, 2008